GSK regains pipeline top spot
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline (GSK) has regained the crown of for the most drugs in development by a pharma company after two years of being displaced by Pfizer, despite reporting a small drop in the number of its R&D products.